Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

1993 • 1,579 citations

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

1998 • 1,338 citations

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

1993 • 1,064 citations

Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus

1992 • 858 citations

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

1997 • 799 citations

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

1996 • 771 citations

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

1995 • 741 citations

Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system

1999 • 733 citations

Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects

1995 • 705 citations

Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing.

1986 • 686 citations

Glucagon-like peptide-1(7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns

1993 • 678 citations

Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man

1993 • 661 citations

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem

1997 • 608 citations

Hamster preproglucagon contains the sequence of glucagon and two related peptides

1983 • 602 citations

Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats

1996 • 581 citations

Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut

1987 • 566 citations

Glucagon-like peptide-1: a potent regulator of food intake in humans

1999 • 564 citations

Exon duplication and divergence in the human preproglucagon gene

1983 • 558 citations

Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide

1995 • 519 citations

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

1998 • 480 citations

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

1986 • 475 citations

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

1993 • 467 citations

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

1999 • 454 citations

Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites

1995 • 451 citations

Gastric emptying and release of incretin hormones after glucose ingestion in humans.

1996 • 416 citations

Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78–107) amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach

1988 • 391 citations

Attenuated GLP-1 secretion in obesity: cause or consequence?

1996 • 374 citations

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

1991 • 371 citations

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

1999 • 343 citations

Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients

1996 • 326 citations

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1998 • 309 citations

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

1996 • 286 citations

Glucagon-Like Peptide I Receptors in the Subfornical Organ and the Area Postrema Are Accessible to Circulating Glucagon-Like Peptide I

1996 • 286 citations

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

1998 • 279 citations

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

1997 • 272 citations

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1995 • 270 citations

The U.K. Prospective Diabetes Study: A review

1998 • 266 citations

Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide

1998 • 260 citations

Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1

1998 • 258 citations

Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the Day

1996 • 255 citations

ENTEROGLUCAGON

1997 • 255 citations

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

1996 • 248 citations

Ileal release of glucagon-like peptide-1 (GLP-1)

1995 • 216 citations

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

1995 • 199 citations

Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity

1997 • 197 citations

Glucagon-like peptide-1 is a physiological incretin in rat.

1995 • 193 citations

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

1994 • 187 citations

Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide

1995 • 180 citations

Proglucagon processing in porcine and human pancreas.

1994 • 167 citations

Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy

1991 • 154 citations

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins

1996 • 154 citations

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1993 • 146 citations

Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia

1998 • 130 citations

The pathogenesis of NIDDM involves a defective expression of the GIP receptor

1997 • 117 citations

Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin—Current status

1983 • 114 citations

GLP-1 does not acutely affect insulin sensitivity in healthy man

1996 • 113 citations

Oxyntomodulin (glicentin-(33–69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs

1988 • 111 citations

Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum

1997 • 99 citations

The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones

1996 • 98 citations

Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus

1997 • 86 citations

Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity.

1983 • 74 citations

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

1998 • 67 citations

Failure of GLP-l(7–36)amide to affect glycogenesis in rat skeletal muscle

1995 • 57 citations

Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide

1995 • 53 citations

Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I

1996 • 47 citations

Cognitive function testing in studies of acute hypoglycaemia: rights and wrongs?

1998 • 40 citations

Human Glucagon-Like Peptide-1 Receptor Gene in NIDDM: Identification and Use of Simple Sequence Repeat Polymorphisms in Genetic Analysis

1994 • 34 citations

Glycation of glucagon-like peptide-1(7-36)amide: characterization and impaired action on rat insulin secreting cells

1998 • 33 citations

Non-linkage of the glucagon-like peptide 1 receptor gene with maturity onset diabetes of the young

1994 • 29 citations

The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones

1996 • 26 citations

Effects of glucagon-like peptide-1 (7-36)amide on insulin stimulated rat skeletal muscle glucose transport

1998 • 19 citations

Human glucagon-like peptide-1 receptor gene in NIDDM. Identification and use of simple sequence repeat polymorphisms in genetic analysis

1994 • 16 citations

The biological significance of “Enteroglucagon”. Present status

1986 • 14 citations

In vitro insulinomimetric effects of GLP‐1 in liver, muscle and fat

1996 • 13 citations

[Human glucagon-like peptide-1 receptor gene in NIDDM].

1994 • 9 citations

Treatment of type 2 diabetes with glucagonlike peptide 1

1998 • 4 citations

Cited By (0)

Loading...